Aaron Wealth Advisors LLC Buys 20,000 Shares of MBX Biosciences, Inc. $MBX

Aaron Wealth Advisors LLC lifted its stake in shares of MBX Biosciences, Inc. (NASDAQ:MBX) by 40.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 70,000 shares of the company’s stock after acquiring an additional 20,000 shares during the quarter. Aaron Wealth Advisors LLC owned approximately 0.16% of MBX Biosciences worth $2,208,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in MBX. Russell Investments Group Ltd. grew its stake in shares of MBX Biosciences by 4,131.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock valued at $26,000 after acquiring an additional 1,446 shares during the period. FNY Investment Advisers LLC purchased a new position in MBX Biosciences in the 3rd quarter worth approximately $27,000. BNP Paribas Financial Markets lifted its holdings in MBX Biosciences by 117.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,896 shares of the company’s stock worth $51,000 after purchasing an additional 1,567 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in MBX Biosciences in the 3rd quarter worth approximately $88,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in MBX Biosciences by 40.3% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,329 shares of the company’s stock worth $106,000 after purchasing an additional 2,682 shares in the last quarter.

Analyst Upgrades and Downgrades

MBX has been the topic of a number of research analyst reports. Guggenheim boosted their price target on MBX Biosciences from $77.00 to $88.00 and gave the stock a “buy” rating in a report on Friday, January 16th. UBS Group reissued a “buy” rating on shares of MBX Biosciences in a report on Tuesday, February 24th. Wall Street Zen raised MBX Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Stifel Nicolaus boosted their price target on MBX Biosciences from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Finally, Truist Financial set a $50.00 price target on MBX Biosciences in a report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $51.56.

Insider Activity

In other news, CEO P. Kent Hawryluk acquired 18,500 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were acquired at an average cost of $28.41 per share, with a total value of $525,585.00. Following the acquisition, the chief executive officer directly owned 486,777 shares of the company’s stock, valued at approximately $13,829,334.57. The trade was a 3.95% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 52.19% of the stock is owned by company insiders.

MBX Biosciences Price Performance

Shares of MBX opened at $31.30 on Tuesday. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of -12.99 and a beta of 1.25. MBX Biosciences, Inc. has a 1 year low of $4.81 and a 1 year high of $44.89. The business’s 50 day simple moving average is $33.20 and its 200-day simple moving average is $28.68.

MBX Biosciences (NASDAQ:MBX) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.15.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.